Quanterix acquired UmanDiagnostics.

Quanterix, a company digitizing biomarker analysis with the goal of advancing the science of precision health, has acquired privately held UmanDiagnostics AB for $22.5m, comprised of $16m in cash plus $6.5m in Quanterix common stock. Uman is widely recognized to possess the leading antibodies available today to measure neurofilament light (Nf-L) and has become the provider of choice for biopharmaceutical and diagnostic applications. “Quanterix has been one of our strongest partners for several years now and its Simoa technology holds the greatest promise for truly unlocking the value of Nf-L. We are proud that our focus on Nf-L has made possible such promising discoveries in neurodegeneration and greatly look forward to further advancing the field as part of Quanterix. We are compelled by Quanterix’ vision, mission, and strategy for disrupting the field of neurodegeneration research and diagnostics and are confident in the management team’s ability to continue its superb execution against this substantial opportunity.” Niklas Norgren, Uman President and CEO.